Running digitally for 2021, the 3rd Treg Directed Therapies Summit is the industry-led meeting focused on targeting and translating Treg modifying therapies with enhanced persistence and durability safely and at scale.
Join this exclusive community online to virtually network and learn from the leading experts in pharma, biotech and academia, to discuss how to robustly modify the Treg response through novel gene engineering and ensure scale and efficiency of cell sorting and isolation for effective cell expansion.
Navigate across 3 days packed with dedicated, interactive formats exploring how to optimize and bring to clinic Treg directed therapies to address huge unmet medical need in autoimmune, allergic, transplant, inflammatory indications.
18-20 May, 2021
9am-5.30pm EST | 6am-2.30pm PST
Drug Developers (Earlybird rates and workshops available): USD 2099.0,
Academic (Earlybird rates and workshops available): USD 1899.0,
Service Providers (Earlybird rates and workshops available): USD 2599.0
Speakers: Adel Nada, CEO, GentiBio, Jeremie Mariau, CEO, ILTOO PHARMA, Jo Viney, Co-Founder, President and CSO, Pandion Therapeutics, Marc Martinez- Llordella, co-Founder and VP Biology, Quell Therapeutics, Wenjun Ouyang, Executive Director, Amgen Inc, Francisco Ramirez-Valle, Executive Director, Bristol-Myers Squibb
Time: 09:00 - 17:30